DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy
Diabetes

Interventions: Drug: liraglutide

First Posted Date: 2012-01-24

Last Posted Date: 2015-01-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 22

Registration Number: NCT01515553

Special Survey for Long Term Application

Completed

Conditions: Achondroplasia
Genetic Disorder

Interventions: Drug: somatropin

First Posted Date: 2012-01-24

Last Posted Date: 2017-02-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 395

Registration Number: NCT01516229

Locations: 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan

Comparison of Three Liraglutide Formulations in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: liraglutide

First Posted Date: 2012-01-23

Last Posted Date: 2017-03-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01514487

Locations: 🇦🇺
Novo Nordisk Investigational Site, Adelaide, Australia

First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy Subjects

Phase 1

Completed

Conditions: Growth Hormone Disorder
Adult Growth Hormone Deficiency
Growth Hormone Deficiency in Children
Healthy

Interventions: Drug: somapacitan
Drug: placebo (somapacitan)

First Posted Date: 2012-01-23

Last Posted Date: 2020-12-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 105

Registration Number: NCT01514500

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: liraglutide

First Posted Date: 2012-01-20

Last Posted Date: 2017-01-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 21

Registration Number: NCT01513525

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec/insulin aspart

First Posted Date: 2012-01-20

Last Posted Date: 2019-03-26

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 394

Registration Number: NCT01513590

Locations: 🇺🇦
Novo Nordisk Investigational Site, Zhytomyr, Ukraine

A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec
Drug: insulin detemir
Drug: insulin aspart

First Posted Date: 2012-01-20

Last Posted Date: 2019-06-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 350

Registration Number: NCT01513473

Locations: 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom

Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: liraglutide
Drug: placebo
Drug: glimepiride

First Posted Date: 2012-01-19

Last Posted Date: 2017-01-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 43

Registration Number: NCT01511692

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: oral anti-diabetic drug
Drug: liraglutide

First Posted Date: 2012-01-19

Last Posted Date: 2017-12-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 363

Registration Number: NCT01512108

Locations: 🇯🇵
Novo Nordisk Investigational Site, Yokohama-shi, Japan

Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers

Phase 1

Withdrawn

Conditions: Growth Disorder
Healthy

Interventions: Drug: somatropin

First Posted Date: 2012-01-19

Last Posted Date: 2013-09-16

Lead Sponsor: Novo Nordisk A/S

Registration Number: NCT01512095

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy